<DOC>
	<DOCNO>NCT00002773</DOCNO>
	<brief_summary>RATIONALE : Vaccines make donated tumor cell treat interferon alfa may make body build immune response kill pancreatic tumor cell . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Colony-stimulating factor may help person 's immune system recover side effect chemotherapy . Combining treatment may kill tumor cell . PURPOSE : Phase II trial study effectiveness combine vaccine therapy use donated tumor cell treat interferon alfa radiation therapy cyclophosphamide plus GM-CSF treating patient advance pancreatic cancer .</brief_summary>
	<brief_title>Vaccine Therapy , Chemotherapy , GM-CSF Treating Patients With Advanced Pancreatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine feasibility , toxicity , antitumor effect active specific intralymphatic immunotherapy allogeneic pancreatic cancer cell treat interferon alfa plus low-dose adjuvant systemic sargramostim ( GM-CSF ) cyclophosphamide patient incurable pancreatic adenocarcinoma . II . Assess immunologic biologic correlate treatment regimen patient . OUTLINE : Cultured allogeneic pancreatic cancer cell incubate interferon alfa 72-96 hour . Autologous cell line , establish , may use alternative . The cell irradiate immediately prior use . Patients receive cyclophosphamide IV day -3 sargramostim ( GM-CSF ) subcutaneously day 0-8 . On day 0 , patient receive viable tumor cell via dorsal pedal lymphatic cannulation . Treatment repeat every 2-4 week minimum 8 week absence disease progression unacceptable toxicity . Patients follow every 2-4 month . PROJECTED ACCRUAL : A total 14 patient accrue study .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma pancreas locoregionally active metastatic amenable cure longterm control surgery , radiotherapy , chemotherapy No brain metastases refractory irradiation surgery PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 03 OR Karnofsky 60100 % Life expectancy : At least 3 month Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Cardiovascular : No prior concurrent significant cardiovascular disease Pulmonary : No prior concurrent significant pulmonary disease Other : No AIDS HIV negative No prior concurrent autoimmune disease No concurrent major medical illness Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics At least 4 week since prior chemotherapy Endocrine therapy : No concurrent chronic steroid therapy Radiotherapy : See Disease Characteristics At least 4 week since prior radiotherapy Surgery : See Disease Characteristics Other : At least 4 week since prior therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>stage II pancreatic cancer</keyword>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>adenocarcinoma pancreas</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>